Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (268)	4/29/2001 6:30:50 PM
From: scaram(o)uche	Respond to of 539

both approaches have merit. certainly, the Myriad statement is (intentionally) naive. neither they nor anyone else can say that disease ass'n has been universally assigned. future applications will virtually fall into the hands of a LSBC-like effort. OTOH, a MYGN-like effort defines pathways, and is a more focused approach to finding targets of known relevance. Both approaches have value. Research premium, MYGN = $1 billion Research premium, LSBC = $15 million I feel that either company would be a great munch.